Schützenhofer Kira, Rack Johannes Gregor Matthias, Ahel Ivan
Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Front Cell Dev Biol. 2021 Nov 15;9:745922. doi: 10.3389/fcell.2021.745922. eCollection 2021.
ADP-ribosylation is a widespread posttranslational modification that is of particular therapeutic relevance due to its involvement in DNA repair. In response to DNA damage, PARP1 and 2 are the main enzymes that catalyze ADP-ribosylation at damage sites. Recently, serine was identified as the primary amino acid acceptor of the ADP-ribosyl moiety following DNA damage and appears to act as seed for chain elongation in this context. Serine-ADP-ribosylation strictly depends on HPF1, an auxiliary factor of PARP1/2, which facilitates this modification by completing the PARP1/2 active site. The signal is terminated by initial poly(ADP-ribose) chain degradation, primarily carried out by PARG, while another enzyme, (ADP-ribosyl)hydrolase 3 (ARH3), specifically cleaves the terminal seryl-ADP-ribosyl bond, thus completing the chain degradation initiated by PARG. This review summarizes recent findings in the field of serine-ADP-ribosylation, its mechanisms, possible functions and potential for therapeutic targeting through HPF1 and ARH3 inhibition.
ADP核糖基化是一种广泛存在的翻译后修饰,由于其参与DNA修复,因而具有特殊的治疗意义。响应DNA损伤时,PARP1和PARP2是在损伤位点催化ADP核糖基化的主要酶。最近,丝氨酸被确定为DNA损伤后ADP核糖基部分的主要氨基酸受体,在此背景下似乎充当链延伸的种子。丝氨酸-ADP核糖基化严格依赖于PARP1/2的辅助因子HPF1,它通过完善PARP1/2活性位点来促进这种修饰。该信号通过初始的聚(ADP-核糖)链降解而终止,主要由PARG进行,而另一种酶(ADP-核糖基)水解酶3(ARH3)则特异性切割末端丝氨酰-ADP-核糖基键,从而完成由PARG引发的链降解。本综述总结了丝氨酸-ADP核糖基化领域的最新发现、其机制、可能的功能以及通过抑制HPF1和ARH3进行治疗靶向的潜力。